Benzinga · Feb 12, 2026
OTC · BTCY
Biotricity, Inc.
Healthcare · Medical - Devices
$0.12
Up+$0.01 (+5.45%)
Updated Aug 15, 2026, 6:34 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 9.75M
- P/E ratio
- -1.89
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 24.1K
- Avg. volume
- 38.23K
Price performance
BTCY price history
1M range · 0 trading sessions · Daily adjusted prices
BTCY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest BTCY news
The latest Smart Investors Daily articles mentioning BTCY.
Stock researchCompany · Overview
BTCY research
Overview
Company profile and research snapshot.
Company profile
BIOTRICITY INC
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $4.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 18, 2024 | HC Wainwright & Co. | Neutral | — |
| Nov 20, 2023 | HC Wainwright & Co. | Neutral | — |
| Jul 5, 2023 | HC Wainwright & Co. | Buy | — |
| Feb 15, 2023 | HC Wainwright & Co. | Buy | — |
| Jul 15, 2022 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Feb 12, 2026
Biotricity Inc (BTCY) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic AI ...
Biotricity Inc (BTCY) reports a 10.2% revenue increase and outlines strategic initiatives for future growth despite ongoing challenges.
Yahoo · Feb 11, 2026
Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA
REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven b
Benzinga · Feb 11, 2026
Biotricity Q3 EPS $(0.04) Beats $(0.08) Estimate, Sales $3.988M Miss $4.100M Estimate
Biotricity (OTC:BTCY) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.08) by 47.5 percent. This is a 740 percent decrease over losses of $(0.01) per share from the same
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
